Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00753909
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
  • Bevacizumab — DRUG
    Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
  • Paclitaxel — DRUG
    Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles

Study Details

This trial will evaluate the efficacy and safety of paclitaxel, carboplatin and bevacizumab combination, administered biweekly, in patients with pretreated, advanced non small cell lung cancer.

Key Dates

First listed
Sep 17, 2008
Start date
Nov 30, 2008
Status verified
Oct 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Paclitaxel/Carboplatin/Bevacizumab

Primary Outcome Measure

Overall Response Rate [ Time Frame: Objective responses confirmed by CT or MRI (on 3rd and 6th cycle) ]

Related Studies